Multiple Sclerosis Drugs Market Growth Outlook Through 2024-2033

Overview and Scope
Multi sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as “”disease-modifying treatments.”” These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells’ propensity for nerve injury may be reduced by this impact.

Sizing and Forecast
The multiple sclerosis drugs market size has grown strongly in recent years. It will grow from $29.66 billion in 2023 to $31.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of multiple sclerosis, unmet medical need, rising investments from pharmaceuticals, growing awareness of multiple sclerosis.

The multiple sclerosis drugs market size is expected to see strongly grown in the next few years. It will grow to $47.97 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing availability of clinical trials, targeted therapy, growing focus on preventive medicine, growing demand for biosimilars, expanding geographical reach, combination therapies:. Major trends in the forecast period include immunomodulatory and immunomodulatory drugs, long-acting formulations, patient-centric care, drug innovation, oral and infusion therapies.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report

Segmentation & Regional Insights
The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
3) By Route Of Administration: Oral Drugs, Parenteral Drugs

North America was the largest region in the global multiple sclerosis drug market in 2023. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=2817&type=smp

Major Driver Impacting Market Growth
The growth of the multiple sclerosis drugs market is aided by the support from the government as well as non-government organizations. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, the government of Alberta in partnership with the Department of Economic Development, Trade, and Tourism in Canada invested $ 1 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of the multiple sclerosis drugs market.

Key Industry Players

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Rebif, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes PLC, Amgen Inc., Apitope Technology (Bristol) Ltd., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

The multiple sclerosis drugs market report table of contents includes:

1. Executive Summary
2. Multiple Sclerosis Drugs Market Characteristics
3. Multiple Sclerosis Drugs Market Trends And Strategies
4. Multiple Sclerosis Drugs Market – Macro Economic Scenario
5. Global Multiple Sclerosis Drugs Market Size and Growth
.
.
.
31. Global Multiple Sclerosis Drugs Market Competitive Benchmarking
32. Global Multiple Sclerosis Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market
34. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis
35. Appendix

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model